Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine

References

• Cardiovascular Disease Statistics2009 Available from: http://www.americanheart.org/presenter.jhtml?identifier=4478. Cited January 13, 2009.
   Google Scholar
• Human Genome Project InformationPharmacogenomics9192008 Available from: http://www.ornl.gov/sci/techresources/Human_Genome/medicine/pharma.shtml. Cited January 13, 2009.
   Google Scholar
• AspinallMGHamermeshRGRealizing the promise of personalized medicineHarv Bus Rev2007851010811716517972499
   PubMed Web of Science ®Google Scholar
• SadéeWDaiZPharmacogenetics/genomics and personalized medicineHum Mol Genet200514Spec No 2R207R21416244319
   PubMed Web of Science ®Google Scholar
• KhouryMJGenetics and genomics in practice: the continuum from genetic disease to genetic information in health and diseaseGenet Med20035426126812865755
   PubMed Web of Science ®Google Scholar
• GinsburgGSDonahueMPNewbyLKProspects for personalized cardiovascular medicine: the impact of genomicsJ Am Coll Cardiol20054691615162716256859
   PubMed Web of Science ®Google Scholar
• ZhangWHuangRSDolanMEIntegrating epigenomics into pharmacogenomic studiesPharmacogenomics and Personalized Medicine2008171420622972
   PubMedGoogle Scholar
• MomaryKCardiovascular pharmacogenomicsJ Pharm Pract2007203265276
   Google Scholar
• CresciSFrom SNPs to functional studies in cardiovascular pharmacogenomicsMethods Mol Biol200844837939318370238
   PubMedGoogle Scholar
• American Medical AssociationWarfarin Drug Label Revisions2007 Available from: http://www.ama-assn.org/ama1/pub/upload/mm/464/warfarin_label_revis.pdf. Cited January 13, 2009.
   Google Scholar
• AndersonJLHorneBDStevensSMCouma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulationCirculation2007116222563257017989110
   PubMed Web of Science ®Google Scholar
• HigashiMKVeenstraDLKondoLMAssociation between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapyJAMA2002287131690169811926893
   PubMed Web of Science ®Google Scholar
• RiederMJReinerAPGageBFEffect of VKORC1 haplotypes on transcriptional regulation and warfarin doseN Engl J Med2005352222285229315930419
   PubMed Web of Science ®Google Scholar
• SconceEAKhanTIWynneHAThe impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimenBlood200510672329233315947090
   PubMed Web of Science ®Google Scholar
• DeGeorgeBRJrKochWJBeta blocker specificity: a building block toward personalized medicineJ Clin Invest20071171868917200711
   PubMed Web of Science ®Google Scholar
• RosskopfDMichelMCPharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicinePharmacol Rev200860451353519074621
   PubMed Web of Science ®Google Scholar
• LiggettSBMialet-PerezJThaneemit-ChenSA polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failureProc Natl Acad Sci U S A200610330112881129316844790
   PubMed Web of Science ®Google Scholar
• SchellemanHKWittemanOHBretelerJCAngiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockersEur J Hum Genet200715447848417299437
   PubMed Web of Science ®Google Scholar
• ScharplatzMPuhanMASteurerJBachmannLMWhat is the impact of the ACE gene insertion/deletion (I/D) polymorphism on the clinical effectiveness and adverse events of ACE inhibitors? – Protocol of a systematic reviewBMC Med Genet200452315361261
   PubMedGoogle Scholar
• ArnettDKDavisBRFordCEPharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) studyCirculation2005111253374338315967849
   PubMed Web of Science ®Google Scholar
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2003. Available from: http://www.nhlbi.nih.gov/guidelines/hypertension/express.pdf. Accessed on January 13, 2009.
   Google Scholar
• ManuntaPBianchiGPharmacogenomics and pharmacogenetics of hypertension: update and perspectives – the adducin paradigmJ Am Soc Nephrol2006174 Suppl 2S30S3516565244
   PubMed Web of Science ®Google Scholar
• PsatyBMSmithNLHeckbertSRDiuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertensionJAMA2002287131680168911926892
   PubMed Web of Science ®Google Scholar
• LynchAIBoerwinkleEDavisBRPharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertensionJAMA2008299329630718212314
   PubMed Web of Science ®Google Scholar
• KajinamiKAkaoHPoliseckiESchaeferEJPharmacogenomics of statin responsivenessAm J Cardiol2005969A65K70K discussion 34K–35K.
   Web of Science ®Google Scholar
• Detection, Evaluation, and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). 2001. Available from: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3xsum.pdf. Cited January 13, 2009.
   Google Scholar
• NieminenTKähönenMViiriLEGrönroosPLehtimäkiTPharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart diseasePharmacogenomics20089101475148618855536
   PubMed Web of Science ®Google Scholar
• ZinehIPharmacogenetics of response to statinsCurr Atheroscler Rep20079318719418241612
   PubMedGoogle Scholar
• KajinamiKBrousseauMENartsuphaCOrdovasJMSchaeferEJATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatinJ Lipid Res200445465365614703505
   PubMed Web of Science ®Google Scholar
• ChasmanDIPosadaDSubrahmanyanLCookNRStantonVPJrRidkerPMPharmacogenetic study of statin therapy and cholesterol reductionJAMA2004291232821282715199031
   PubMed Web of Science ®Google Scholar
• ZhuHTuckerHMGrearKEA common polymorphism decreases low-density lipoprotein receptor exon 12 splicing efficiency and associates with increased cholesterolHum Mol Genet200716141765177217517690
   PubMed Web of Science ®Google Scholar
• United States Food and Drug AdministrationFDA News Release: FDA Approves Updated Warfarin (Coumadin) Prescribing Information. New Genetic Information May Help Providers Improve Initial Dosing Estimates of the Anticoagulant for Individual PatientsWhite Oak, MDUS FDA8162007
   Google Scholar